Achieve Life Sciences Inc ACHV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACHV is a good fit for your portfolio.
News
-
Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference
-
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update
-
Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
-
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024
-
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
-
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
-
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
-
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission
Trading Information
- Previous Close Price
- $4.41
- Day Range
- $4.35–4.59
- 52-Week Range
- $3.03–10.30
- Bid/Ask
- $4.23 / $4.50
- Market Cap
- $154.13 Mil
- Volume/Avg
- 51,613 / 100,522
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 22
Comparables
Valuation
|
Metric
|
ACHV
|
ICVX
|
HLVX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 3.30 | 2.30 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ACHV
ICVX
HLVX
Financial Strength
|
Metric
|
ACHV
|
ICVX
|
HLVX
|
|---|---|---|---|
Quick Ratio | 0.75 | 17.59 | 10.37 |
Current Ratio | 0.82 | 18.06 | 10.62 |
Interest Coverage | −9.74 | — | −54.72 |
Quick Ratio
ACHV
ICVX
HLVX
Profitability
|
Metric
|
ACHV
|
ICVX
|
HLVX
|
|---|---|---|---|
Return on Assets (Normalized) | −104.74% | −29.30% | −34.03% |
Return on Equity (Normalized) | −614.40% | −31.87% | −42.52% |
Return on Invested Capital (Normalized) | −116.13% | −34.69% | −38.62% |
Return on Assets
ACHV
ICVX
HLVX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dxhnymrq | Pqnws | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kshczvffw | Qjcdvd | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mjysyxl | Kdvkqv | $98.8 Bil | |
MRNA
| Moderna Inc | Xtlvtfnl | Zxlp | $38.8 Bil | |
ARGX
| argenx SE ADR | Qyzgnpnn | Gfpk | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Czkwlns | Ntvv | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lmdxcnwrl | Dqgyjl | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ggnzryfp | Msnmkps | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lmhxcghxrp | Sctdnqf | $12.4 Bil | |
INCY
| Incyte Corp | Nbjcsnpcj | Jrrgyvy | $11.9 Bil |